Literature DB >> 25838081

Toll-like receptor 9 expression in the natural history of Barrett mucosa.

Heikki Huhta1, Olli Helminen, Joonas H Kauppila, Heikki Takala, Kalervo Metsikkö, Petri Lehenkari, Juha Saarnio, Tuomo Karttunen.   

Abstract

Increased expression of TLR9 in esophageal adenocarcinoma and squamous cell carcinoma correlates with poor prognosis. We have explored the expression and suspected that TLR9 activation might contribute to pathogenesis in esophageal columnar metaplasia-dysplasia-neoplasia sequence, and hence, we have studied the usefulness of TLR9 as a marker for dysplasia. We have determined the expression of TLR9 in specimens with normal esophagus (n = 89), gastric (n = 71), or intestinal metaplasia (n = 56) without dysplasia, and low-grade (n = 51) or high-grade dysplasia (n = 40), and esophageal adenocarcinoma (n = 88). We observed linearly increasing TLR9 expression in specimens to be associated with change from normal epithelium to columnar metaplasia and further to dysplasia. ROC curve analysis showed clinically irrelevant sensitivity of 71% and specificity of 67% for TLR9 intensity in detection of low-grade dysplasia. Membrane-associated TLR9 expression detected by immunohistochemistry and immunofluorescence was predominantly associated with foveolar-type dysplasia as detected by HE staining (p = 0.015). TLR9 is expressed in Barrett's esophagus, and dissolution of TLR9 staining increases from nondysplastic epithelium to dysplastic. TLR9 may serve as a new way of recognizing the histopathological origin of dysplasia (adenomatous vs foveolar) with observed subcellular pattern of TLR9.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25838081     DOI: 10.1007/s00428-015-1770-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  41 in total

1.  American Gastroenterological Association medical position statement on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

2.  Site differences of Toll-like receptor expression in the mucous epithelium of rat small intestine.

Authors:  Y Mantani; A Kamezaki; K G S Udayanga; E-i Takahara; W M Qi; J Kawano; T Yokoyama; N Hoshi; H Kitagawa
Journal:  Histol Histopathol       Date:  2011-10       Impact factor: 2.303

3.  Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13.

Authors:  S Nurmenniemi; P Kuvaja; S Lehtonen; S Tiuraniemi; I Alahuhta; R K Mattila; J Risteli; T Salo; K S Selander; P Nyberg; P Lehenkari
Journal:  Exp Cell Res       Date:  2010-05-27       Impact factor: 3.905

4.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

5.  The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker.

Authors:  Rosaria Cammarota; Valentina Bertolini; Giuseppina Pennesi; Eraldo O Bucci; Ornella Gottardi; Cecilia Garlanda; Luigi Laghi; Massimo C Barberis; Fausto Sessa; Douglas M Noonan; Adriana Albini
Journal:  J Transl Med       Date:  2010-11-08       Impact factor: 5.531

6.  Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome.

Authors:  Liying Yang; Xiaohua Lu; Carlos W Nossa; Fritz Francois; Richard M Peek; Zhiheng Pei
Journal:  Gastroenterology       Date:  2009-04-23       Impact factor: 22.682

7.  Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus.

Authors:  Marjon Kerkhof; Ewout W Steyerberg; Johannes G Kusters; Herman van Dekken; Adriana J van Vuuren; Ernst J Kuipers; Peter D Siersema
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

8.  The expression and function of Toll-like receptors 3 and 9 in human colon carcinoma.

Authors:  Keiichiro Nojiri; Kazushi Sugimoto; Katsuya Shiraki; Masahiko Tameda; Yuuji Inagaki; Satoko Kusagawa; Suguru Ogura; Junichiro Tanaka; Misao Yoneda; Norihiko Yamamoto; Hiroshi Okano; Yoshiyuki Takei; Masaaki Ito; Chika Kasai; Hidekazu Inoue; Koujiro Takase
Journal:  Oncol Rep       Date:  2013-03-04       Impact factor: 3.906

Review 9.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 10.  Toll-like receptors in esophageal cancer.

Authors:  Joonas H Kauppila; Katri S Selander
Journal:  Front Immunol       Date:  2014-05-07       Impact factor: 7.561

View more
  9 in total

1.  Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.

Authors:  Didier Meseure; Sophie Vacher; Kinan Drak Alsibai; Martine Trassard; André Nicolas; Renaud Leclere; Florence Lerebours; Jean Marc Guinebretiere; Elisabetta Marangoni; Rosette Lidereau; Ivan Bieche
Journal:  Cancer Microenviron       Date:  2016-07-09

2.  High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.

Authors:  Joni Leppänen; Olli Helminen; Heikki Huhta; Joonas H Kauppila; Joel Isohookana; Kirsi-Maria Haapasaari; Petri Lehenkari; Juha Saarnio; Tuomo J Karttunen
Journal:  Virchows Arch       Date:  2017-02-12       Impact factor: 4.064

3.  Nucleic acid-sensing toll-like receptors 3, 7 and 8 in esophageal epithelium, barrett's esophagus, dysplasia and adenocarcinoma.

Authors:  Olli Helminen; Heikki Huhta; Petri P Lehenkari; Juha Saarnio; Tuomo J Karttunen; Joonas H Kauppila
Journal:  Oncoimmunology       Date:  2016-01-25       Impact factor: 8.110

4.  A non-endoscopic device to sample the oesophageal microbiota: a case-control study.

Authors:  Daffolyn R Fels Elliott; Alan W Walker; Maria O'Donovan; Julian Parkhill; Rebecca C Fitzgerald
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-11-12

5.  Intratumoral lactate metabolism in Barrett's esophagus and adenocarcinoma.

Authors:  Heikki Huhta; Olli Helminen; Sami Palomäki; Joonas H Kauppila; Juha Saarnio; Petri P Lehenkari; Tuomo J Karttunen
Journal:  Oncotarget       Date:  2017-04-04

6.  Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma.

Authors:  Joni Leppänen; Olli Helminen; Heikki Huhta; Joonas H Kauppila; Joel Isohookana; Kirsi-Maria Haapasaari; Seppo Parkkila; Juha Saarnio; Petri P Lehenkari; Tuomo J Karttunen
Journal:  World J Surg Oncol       Date:  2018-07-04       Impact factor: 2.754

7.  The Expression of Toll-like Receptors in Normal Human and Murine Gastrointestinal Organs and the Effect of Microbiome and Cancer.

Authors:  Heikki Huhta; Olli Helminen; Joonas H Kauppila; Tuula Salo; Katja Porvari; Juha Saarnio; Petri P Lehenkari; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2016-07-01       Impact factor: 2.479

8.  Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.

Authors:  Heikki Huhta; Olli Helminen; Petri P Lehenkari; Juha Saarnio; Tuomo J Karttunen; Joonas H Kauppila
Journal:  Oncotarget       Date:  2016-04-26

9.  Divergent expression of bacterial wall sensing Toll-like receptors 2 and 4 in colorectal cancer.

Authors:  Karoliina Paarnio; Sara Väyrynen; Kai Klintrup; Pasi Ohtonen; Markus J Mäkinen; Jyrki Mäkelä; Tuomo J Karttunen
Journal:  World J Gastroenterol       Date:  2017-07-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.